Alessa Therapeutics Receives FDA Fast Track Status for Enolen in Localised Prostate Cancer
Friday, January 09, 2026
Alessa Therapeutics, a clinical-stage biopharmaceutical company developing local drug delivery technologies for early-stage prostate cancer, has received Fast Track designation from the US Food and Drug Administration for Enolen. The product is being developed to treat low- to intermediate-risk localised prostate cancer.
The FDA grants Fast Track status to therapies intended for serious or life-threatening conditions that may address unmet medical needs. The designation is designed to support faster development and review. It allows for closer interaction with the FDA and may enable rolling review of a future marketing application.
The designation highlights the need for new treatment options for men with early-stage prostate cancer, particularly for patients who currently face a choice between active surveillance and more aggressive treatments that often cause significant side effects.
Enolen is based on anti-androgen releasing implants that contain enzalutamide, an FDA-approved prostate cancer drug. The therapy uses Alessa’s proprietary local delivery technology to release the drug directly into prostate tissue. This approach is intended to reduce the risk of side effects linked to systemic anti-androgen and testosterone-lowering therapies, such as sexual dysfunction, loss of muscle mass, cognitive problems, metabolic issues and cardiovascular complications.
Preclinical and clinical data to date show that the implant technology can provide continuous and long-lasting delivery of anti-cancer agents. This allows high drug levels at the disease site while limiting exposure to the rest of the body.
Enolen is currently being evaluated in a Phase 1 clinical trial assessing its safety, tolerability and early signs of effectiveness for sustained local delivery of enzalutamide to the prostate. Alessa plans to share initial study results in 2026.
Source: businesswire.com
